Recent molecular studies indicate that aerobic glycolysis plays an important role in tumorigenesis and is a valid target for cancer therapy.
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Although 2-DG is wellcharacterized as a glycolytic inhibitor, we recently discovered that it activates a prosurvival oncoprotein, AKT, through PI3K. In this study, we discovered that 2-DG treatments disrupted the binding between IGF-1 and IGFBP3 so that free form of IGF-1 could be released from IGF-1/IGFBP3 complex to activate IGF1R signaling. Because of IGF1R signaling is involved, PI3K/AKT only constituted one of the prosurvival pathways that are activated by 2-DG treatment, and we validated that that MEK-ERK signaling was also induced in an IGF1R-dependent manner.
Furthermore, our phospho-specific antibody microarray analysis indicated that 2-DG upregulated the phosphorylation of 64 sites within various signaling pathways. Chemical inhibition of IGF1R reduced 57 of these upregulations. These data suggested that 2-DG induced activation of many survival pathways can be jointly attenuated through IGF1R inhibition. Our in vitro analysis demonstrated that treatment with a combination of sub-toxic doses of 2-DG and the IGF1R inhibitor II reduced cancer cell proliferation 90% and promoted significant apoptosis.
Cancer cells display high rates of aerobic glycolysis in comparison to their nontransformed counterparts [i.e. the Warburg Effect, and ref (1) ]. Whether increased aerobic glycolysis drives tumor formation or merely represents a byproduct of oncogenic transformation was a subject of controversy. Two recent studies demonstrated that the Warburg Effect can be reversed in some cancer cells by either the depletion of lactate dehydrogenenase A (LDH-A) or switching pyruvate kinase expression from M2 to M1 isoform (2, 3) . Interestingly, the reversal of the Warburg effect correlates with a reduction in the ability of the isogenic cancer cells to form tumors in nude mouse xenografts. Viewed in combination, these observations appeared to indicate that tumor cells preferentially use glucose for purposes other than oxidative phosphorylation and that aerobic glycolysis is a valid target for cancer therapeutics.
Targeting glycolysis for cancer treatment has been previously explored as a therapeutic approach (4, 5) . Of all the glycolysis inhibitors that were evaluated, 2-deoxyglucose (2-DG) is the one that has been best characterized in animal model studies and human clinical trials (6) (7) (8) .
It is converted by hexokinase to phosphorylated 2-DG (2-DG-P), which becomes trapped inside the cell and inhibits hexokinase (9) . As a direct consequence of 2-DG treatment, intracellular ATP is depleted (10, 11) , which ultimately suppresses cell proliferation in vitro (12, 13) . Nonetheless, the implementation of 2-DG as an anticancer agent in vivo has been a disappointment. Whereas 2-DG suppresses cell growth in vitro, studies using xenografts indicate that 2-DG treatment, when provided as a single agent, does not inhibit tumor growth (6).
Because 2-DG is a small molecule, we suspected it activates other signaling pathways and decided to evaluate its off-target effects. Our initial findings indicated that 2-DG activates AKT function through phosphatidylinositol-3-kinase (PI3K) and is independent of glycolysis or mTOR inhibition. Thus, the inhibitory effect on growth produced by 2-DG-mediated glycolysis inhibition may be partial offset by the fact there is also 2-DG-induced AKT activation (14) .
In current study, we used a phosphospecific antibody array to identify IGF1R as the upstream receptor tyrosine kinase that is responsible for the activation of AKT signaling. Using recombinant IGF-1 and IGFBP3 proteins, we discovered that the inhibition of IGF-1 by IGFBP3 is disrupted in the presence of 2-DG. As 2-DG treatment activates IGF-1 signaling, we evaluated other pro-survival signaling pathways, such as ERK signaling, which was also activated by 2-DG treatment. Lastly, we tested to see if blocking of IGF1R interfered with the pro-survival pathways and increased apoptosis, if given in combination with 2-DG.
Experimental Procedures
Materials-2-deoxyglucose, rabbit polyclonal anti-actin antibody, and recombinant IGF-1 were purchased from Sigma-Aldrick (St. Louis, MO). Erlotinib, LY294002, U0126 and PB98059 (MEK inhibitors) were purchased from LC Laboratories (Woburn, MICROARRAY). IGF1R inhibitor II (cat#407248), αIR3 (an IGF1R antibody) and PP2 were purchased from Calbiochem (Darmstadt, Germany). Recombinant IGFBP3 was purchased from GenWasy Biotech Inc (San Diego, CA). Active Free IGF-1 ELISA kit was purchased from Beckman Coulter (Fullerton, CA). Antibodies against AKT, phospho-AKT (p-AKTSer473), ERK, phospho-ERK (p-p44/42T202/Y204), Caspase-3 and IGF1R were purchased from Cell Signaling Technology, Inc. (Beverly, MA). Cell lines and Cell Culture-Non-small cell lung cancer (NSCLC) cell lines (H460, A549, H157, H23, H1299, H1792, H358, Calu-1, H226, H522, HOP92, H596 H322M), breast cancer cell line (T-47D), cervical cancer cell line (HeLa), melanoma cell line (MDA-MB-435), and colorectal cancer cell line (HCT116) were purchased from the American Type Culture Collection (ATCC) (Manassas, VA, USA) and were propagated according to the conditions recommended by ATCC. Phospho-specific Protein Microarray analysisPhospho-specific Protein Microarray was obtained from Full Moon Biosystems, Inc. Protein microarray analysis was carried out using a previously described protocol which is included in the supplements (15) . Western Blot Analysis-The procedures for preparation of whole cell protein lysates and for Western blotting were performed as described previously (14) . The same blots were used for probing phospho-specific antibodies and antibodies against total protein. Actin was used as loading controls. The western analyses present in this study were carried out at least twice, and representative images were shown in the figures. For quantitation analysis, the density of phospho-AKT, total AKT, phospho-ERK and total ERK was determined by ImageJ from NIH (http://rsbweb.nih.gov/ij/). Phosphorylation ratio was calculated using the following formula: Transient siRNA transfection-IGF1R siRNA duplexes were purchased from Applied Biosystems (Foster City, CA, USA). Transient IGF1R knockdown were performed as previously described, which is also included in the supplements (14 
RESULTS

Phospho-antibody microarray analysis of 2-DG-induced protein phosphorylation.
We previously demonstrated that 2-DG treatment activates the AKT function in seven NSCLC, one colorectal cancer cell line (HCT116), one melanoma cell line (M14/MDA-MB-435), two breast cancer cell lines (T-47D and MCF-7) and one cervical cancer cell line (HeLa) (14) . In this manuscript, we also discovered 2-DG induced AKT phosphorylation in six more NSCLC cell lines (Supplemental Figure 1A) ; therefore, the induction of AKT phosphorylation by 2-DG is a common phenomenon in NSCLC and other cancer cell lines.
To identify the upstream molecules that are responsible for 2-DG-induced AKT activation, we used a customized phospho-specific antibody microarray from Full Moon Biosystems. This array interrogates phosphorylation sites on 15 receptor/cytoplasmic tyrosine kinases/tyrosine kinase adaptors, as well as 100 phosphorylation sites in various downstream signaling pathways. Each site was evaluated using a pair of antibodies against both the phosphorylated and unphosphorylated site, and every antibody was spotted in replicates of six. Based on these features, a software program (PANDA) was developed that would allow us to quantitatively evaluate the phosphorylation change at each site with a 95% confidence interval (see supplemental methods). H460 cells treated with 2-DG responded with a statistically significant upregulation of 7 receptor/cytoplasmic tyrosine kinases (Table 1 ). In addition to confirming the activation of PI3K/AKT signaling by 2-DG, this method allowed us to determine that 2-DG treatment also induced the phosphorylation of Raf-MEK-ERK kinases or their targets (10 sites/9 proteins), cell-cycle/DNA-damage checkpoint proteins (6 sites/5 proteins), and Jak/Stat proteins (5 sites/5 proteins). In total, we discovered that the phosphorylation of 64 sites (56%) became elevated following 2-DG treatment (Table 1) . Therefore, the off-target effects of 2-DG were broader than we had initially anticipated.
2-DG induces AKT phosphorylation through IGF1R but not EGFR or Src.
Because 2-DG treatment enhanced the phosphorylation of several receptor tyrosine kinases, we next sought to determine whether a specific receptor is responsible for the induction of AKT phosphorylation. We first used erlotinib, an EGFR inhibitor. Because this compound failed to block 2-DG-induced AKT phosphorylation in H460 and H1299 cells ( Figure 1A ), we were able to confirm in new cell lines our previous observation that in H1650 cells, EGFR was unlikely to be involved in 2-DG-induced AKT activation (14) . As Src is a tyrosine kinase that mediates multiple signal transduction pathways (16) , we next evaluated the effect of PP2, a Src inhibitor, on 2-DG induced AKT phosphorylation. However, pre-treatment of H460 and H157 cells with PP2 did not block 2-DG-induced AKT phosphorylation either ( Figure 1B ), indicating that Src was also not required for this induction process.
Finally, we evaluated whether the inhibition of IGF1R function could inhibit 2-DG-induced AKT phosphorylation. Initially, we pre-treated the NSCLC cell lines H1299, H157, H460, A549 and Calu-1 with a specific inhibitor of IGF1R, IGF1R inhibitor II, and found this inhibitor blocked 2-DG-induced AKT phosphorylation ( Figure 1C) .
A similar inhibition was also observed in cell lines representing other cancer types, such as HCT116, HeLa, T-47D and MDA-MB-435 cells (Supplemental Figure 2) . To directly evaluate the role of IGF1R, we pre-treated H460 and H1299 cells with an IGF1R antibody, αIR3. We found this antibody also blocked 2-DG-induced AKT phosphorylation ( Figure  1D ). Alternatively, IGF1R was transiently depleted in H460 cells using siRNA, and this depletion of IGF1R expression also inhibited 2-DG-induced AKT phosphorylation ( Figure 1E ). Therefore, we found that IGF1R is required for 2-DGinduced AKT phosphorylation in several cancer cell types including NSCLC.
2-DG treatment releases the suppression of IGF-1-mediated AKT phosphorylation by IGFBP3.
We next set to determine whether ligand binding is required for 2-DG induced AKT phosphorylation. First, H460 cells were treated with 25 mM 2-DG in presence of 10%, 1% or 0% fetal bovine serum for 1 hour. The level of AKT phosphorylation significantly correlated with the percentage of serum included in culture media (Figure 2A ), indicating that IGF1R ligands are required for 2-DG induced AKT phosphorylation. In serum-free condition, 2-DG induced AKT phosphorylation was only observed with extended film exposure ( Figure  2A , comparing lane 5 with 6). This data indicated that H460 cells are unlikely to secrete significant amount of IGF1R ligands in response to 2-DG treatment.
IGF-1 is a major IGF1R ligand, and the binding of IGF-1 to IGF1R also activates AKT phosphorylation (17) . Less than 1% IGF-1 is present in serum in free form because the majority of circulating IGF-1 is bound to plasma IGF binding proteins (IGFBPs), particularly IGFBP-3 (18) . The complex between IGF-1 and IGFBP-3 prolongs the half-life of IGF-1 and modulates the interaction between IGF-1 and IGF1R. We next tested how IGF-1 induced AKT was affected by 2-DG and IGFBP3 treatment. H460 cells were serum starved for 12 hours.
Treatment with 200 ng/ml of recombinant IGFBP3 did not alter AKT phosphorylation ( Figure 2B To directly assess whether 2-DG interferes with the interaction between IGF-1 and IGFBP3, we used a Free IGF-1 ELISA assay that was specifically designed to detect the free form IGF-1 but not the ones in the IGF-1/IGFBP3 complex. The inclusion of 25 mM 2-DG with 100 pg of IGF-1 did not affect the detection of free IGF-1 by the ELISA assay. 100 pg of free IGF-1 was incubated with 20 ng of recombinant IGFBP3, and the recombinant IGFBP3 sequestered the majority of IGF-1 so that only 2.2 pg of free-IGF-1 could be detected in the presence of IGFBP3 ( Figure 2C ). The addition of 1 mM 2-DG did not affect the formation of this complex, but the inclusion of 5 mM 2-DG increased the detectable free IGF-1 to 5.3 ng, which represent a 141% increase. Treatment with 25 mM 2-DG led to the detection of 62 pg of free IGF-1 ( Figure 2C ). This data indicated that the binding between IGF-1 and IGFBP3 can be disrupted by 2-DG treatment in a dose dependent manner. Figure 3A) . We also found that 2-DG did not transiently induce ERK phosphorylation, because it remained elevated: ERK phosphorylation continued to be observed even 8 to 24 hr after the addition of 2-DG ( Figure 3B ). It is of note that oral administration of 300 mg/kg of 2-DG will produce about 5.5 mM 2-DG in patient blood (8) , and our dose analysis indicated that a treatment of only 2.5 mM 2-DG was sufficient to induce ERK phosphorylation in H157, H1299 and H460 cells ( Figure 3C ). Therefore, we found that 2-DG induces ERK phosphorylation in these cancer cells at a pharmacologically relevant concentration. In addition, we also observed 2-DG induced ERK phosphorylation in A549, H23, M14/MDA-MB-435, H1792 and H358 cells ( Figure 3D ), so this activity by 2-DG occurs after treatment of many cancer cell lines.
2-DG induces time-and dose-dependent ERK phosphorylation.
2-DG also induces ERK phosphorylation through IGF1R and MEK.
We wished to determine whether the observed 2-DG-induced ERK phosphorylation is directly mediated by MEK. First, we evaluated the effect of U0126 in H1299 and H460 cells. The use of U0126, a highly selective inhibitor of both MEK1 and MEK2, was capable of blocking 2-DG-induced ERK phosphorylation in both cell lines ( Figure  4A, left panel) . In addition, we found that 2-DG-induced ERK phosphorylation was also blocked by another MEK inhibitor, PD98059, in both H460 and H157 cells ( Figure 4A , right panel), indicating that MEK was involved in the process.
We also sought to define the role of IGF1R in 2-DG-induced ERK phosphorylation. Use of IGF1R inhibitor II also blocked ERK phosphorylation in H1299, H157, H460 and MDA-MB-435 cells, following 2-DG treatment ( Figure 4B ). This suggested that the increase in ERK phosphorylation was mediated by IGF1R. Furthermore, we found that IGF1R antibody blocked 2-DG-induced ERK phosphorylation in H460 and H1299 cells ( Figure 4C ), and the depletion of IGF1R expression in H157 cells by siRNA correlated with an attenuation of 2-DGinduced phosphorylation ( Figure 4D ). Erlotinib; however, did not block 2-DG-induced ERK phosphorylation, indicating that EGFR signaling was not essential for 2-DG-induced ERK phosphorylation (data not shown).
In combination, these data suggested that 2-DG--induced ERK phosphorylation is mediated through its activity on IGF1R and MEK.
Majority of 2-DG-induced phosphorylation is inhibited by IGF1R inhibitor II.
We subsequently evaluated the effect of IGF1R inhibitor II on 2-DG-induced phosphorylation in the other signaling pathways found to be active with the phospho-specific antibody array. While 2-DG induced the phosphorylation of IGF1R at Tyr1161 by 1.8-fold, pre-treatment with IGF1R inhibitor II reduced that phosphorylation ratio down to 1.2-fold.
In fact, of the 64 phosphorylation sites that were elevated by 2-DG treatment alone, pre-treatment with IGF1R inhibitor II was found to reduce phosphorylation in 57 (89%) of the sites (Table 1 ). This data suggested that the counterproductive off-target effects of 2-DG therapy due to enhanced protein phosphorylation could be attenuated by pretreatment with IGF1R inhibitor II. Interestingly, we also found that the basal phosphorylation levels of these 64 sites were mostly unaffected [87.5% (56/64)] in cancer cells that were treated solely with this inhibitor (IGF1R inhibitor II alone) (Table I) .
Combined inhibition of glycolysis and IGF1R induces synergistic cell killing. The inhibition of glycolysis negatively impacts cell growth (5) . We have previously demonstrated that 2-DG-mediated growth suppression is partially offset by concomitant 2-DG-induced AKT activation, in H1299 cells (14) . Similar partial growth suppression was observed in H460 and H157 cells, when 2-DG was combined with LY294002 ( Figure 5A , top panels); however, LY294002 did not alter 2-DGinduced ERK phosphorylation, so PI3K/AKT signaling was not involved in the regulation of 2-DG-induced ERK phosphorylation ( Figure 5B , top panels).
We assessed whether 2-DG-mediated growth suppression was negatively impacted specifically by 2-DG-induced ERK phosphorylation. Subtoxic doses of U0126 and 2-DG were used in this experiment. While the combination of 5 mM 2-DG and the various doses of U0126 led to increases in growth suppression in two NSLCLC cell lines, such combinations did not substantially suppress cell proliferation ( Figure 5A, middle panel) . As U0126 is specific for MEK, and we did not observe any inhibition on 2-DG-induced AKT phosphorylation, known to be mediated by PI3K (Figure 5B ), these data indicated that the activation of both AKT and ERK signaling by 2-DG did promote cell survival, but targeted inhibition of either PI3K/AKT or MEK/ERK alone was not sufficient to substantially negate the cell survival effect that 2-DG induced.
Because the IGF1R inhibitor II reversed the majority of phosphorylation sites induced by 2-DG treatment, we evaluated whether the combined inhibition of both glycolysis and IGF1R functions that were involved in promoting tumor growth would result in a synergistic inhibition of cell proliferation. We first determined the effects of combined inhibition of glycolysis and IGF1R on cell proliferation. While a single dose of 2-DG (5 mM) or IGF1R inhibitor II (5 or 10 μM) resulted in approximately 20-30% cell growth inhibition for H460 cells, the combination of 5mM 2-DG and 10 μM IGF1R inhibitor II resulted in over 90% growth inhibition for these cancer cells (Fig.  5A, bottom panel) . A similar synergistic effect with respect to enhanced growth inhibition was observed in H157 cells.
We also sought to determine whether apoptosis was induced by the combination of 2-DG and IGF1R inhibitor II, because apoptosis was not observed when 2-DG was combined with LY294002 (data not shown). First, an apoptosis-based immunoblot assay was used to determine whether caspase-3 cleavage was induced by this combination.
Neither the control 5 mM 2-DG nor 10 μM IGF1R inhibitor II treatments alone led to caspase 3 cleavage even 48 hours after treatment, but significant caspase 3 cleavage was detected when these two compounds were used in combination (Fig. 5B,  bottom panel) . Additionally, apoptosis was evaluated by 7AAD and Annexin V analysis, where the combination of sub-toxic doses of 2-DG and IGF1R inhibitor II resulted in a synergistic increase in the number of cells that underwent apoptosis (Fig. 5C) . Therefore, the combination of sub-toxic doses of 2-DG and IGF1R inhibitor not only inhibited cell proliferation, but was also found to promote apoptosis.
DISCUSSION
Recent molecular biology studies indicate that aberrantly active aerobic glycolysis is required for tumorigenesis (2,3) ; therefore, aerobic glycolysis is a valid target for cancer therapy.
2-DG is the best characterized glycolytic inhibitor, and the proper use of 2-DG in human subjects was previously determined in a Phase I/II clinical trial in India (7, 8) . As the therapeutic potential of 2-DG in combination therapy prompted enough interest in the United States, three phase I clinical trials for this compound are ongoing (Clinical-Trials.gov identifier: NCT00096707, NCT00247403, and NCT00247403).
Because there had been limited therapeutic efficacy for 2-DG as a single agent in preclinical models, we were led to question and explore the pro-survival effects of 2-DG treatment. We initially discovered that 2-DG induces AKT activation within 15 minutes and that this activation is mediated by PI3K (14) . Because PIK3CA and PTEN mutations are relatively rare in lung cancer (21) , most NSCLC cell lines have relatively low constitutive AKT phosphorylation. Indeed, when surveyed in our current expanded analysis, we found that 87% (13/15) of NSCLC cells had increases in AKT phosphorylation after 2-DG treatment.
In this study, we employed a novel phosphospecific antibody microarray to identify the upstream signaling molecule/s involved in 2-DG-induced AKT activation.
This antibody microarray evaluates 115 distinct phosphorylation sites in various signal transduction pathways, and the use of six replicates per antibody allowed us to identify statistically significant alterations. Our analysis revealed seven receptor tyrosine kinases as potential candidates due to significant changes in their phosphorylation, and IGF1R was subsequently verified as the upstream receptor tyrosine kinase responsible for the 2-DGinduced AKT phosphorylation that we had originally observed. Therefore, we discovered that IGF1R/PI3K/AKT constitutes a signaling pathway that becomes activated by 2-DG treatment in the majority of NSCLC cells.
Another interesting finding of this work is the mechanism by which 2-DG activates IGF1R/PI3K/AKT signaling. The majority of circulating IGF-1 is bound to plasma IGF binding proteins (IGFBPs) which prolongs the half-life of IGF-1 and alters the binding of IGF-1 to IGF1R (17) . Our data indicated that 2-DG treatment releases the suppression of IGF-1 mediated AKT phosphorylation by IGFBP3. The Free IGF-1 ELISA assay revealed that 2-DG disrupts the interaction between IGF-1 and IGFBP3 so that free form of IGF-1 can be released from IGFBP3 binding. However, 2-DG did not appear to interfere with the interaction between IGF-1 and IGF1R because the combination of 2-DG and IGF-1 also induced a significant elevation in AKT phosphorylation ( Figure 2B, lane 8) . Therefore, 2-DG treatment results in the release of free IGF-1 to activate IGF1R signaling.
Because IGF-1/IGF1R is also involved in the activation of other signaling pathways (23), we also evaluated their activation statuses and discovered that 2-DG induced ERK phosphorylation in seven of the NSCLC cell lines and one melanoma cell line. Similar to the findings on activation of PI3K/AKT signaling, 2-DG activated ERK signaling within 15 minutes at pharmacologically relevant concentrations, and IGF1R was found to be essential for the activation of MEK-ERK signaling by 2-DG.
The activations of AKT and ERK signals have been previously shown to promote cell survival (24,25). Consistent with these previous studies, we did observe an enhancement in growth suppression when 2-DG was combined with either PI3K or MEK inhibitors. However, for each, such enhancements were not substantial, suggesting that both signaling pathways were contributing to cancer cell survival. We did not evaluate a three-way combination of 2-DG and those inhibitors, LY294002 and U0126, because our phosphoantibody microarray analysis indicated that 2-DG treatment led to a statistically significant elevation of phosphorylation in several other signaling pathways as well, such as Jak/Stat or NFκB, so it was possible that the activation of these other signaling pathways could also contribute to enhanced cell survival. Instead, we focused on the possibility of using a single agent as an inhibitor: Because a chemical inhibitor of IGF1R attenuated the 2-DG-induced phosphorylation in 89% (57/64) of the sites having enhanced phosphorylation in our microarray, we believe that a better experimental strategy is to combine 2-DG with IGF1R inhibitor II.
When we used sub-toxic doses of 2-DG and IGF1R inhibitor II to treat H460 and H157 cells, this combination inhibited cell proliferation by 90% in both cell lines.
In addition, the appearance of caspase-3 cleavage and apoptotic cells indicated that a significant portion of the inhibitory effect on growth was due to apoptosis. Therefore, we believe that we have clearly demonstrated that IGF1R is a key mediator for cell survival after 2-DG treatment, and our in vitro data suggests that the inclusion of an IGF1R inhibitor in 2-DG-based therapies may represent the optimal step to synergistically improve treatment efficacy with this drug. . H460 and H1299 cells were pre-treated with 5 μg/ml αIR3 for 30 minutes before the addition of 2-DG. (E) siRNA against IGF1R was used to deplete the expression of IGF1R in H460 cells, and anti-IGF1R antibody was used to evaluate the extent of IGF1R depletion. Cells were harvested 4 hrs after 25 mM 2-DG treatment and analyzed by immunoblot. Band intensity was quantified by densitometry, phosphorylation changes was expression by a ratio using a formula described in method section. 
